Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AE 37

Drug Profile

AE 37

Alternative Names: AE37; AE37 peptide/GM-CSF HER2 peptide vaccine; AE37 vaccine; Cancer vaccine AE37 - Generex-Biotechnology; Cancer vaccine AE37 - NuGenerex Imuuno-Oncology; Cancer vaccine HER2/neu Antigen Express AE37; Cancer vaccine HER2/neu Generex Biotechnology AE37; Her-2/neu Breast cancer; Her-2/neu Prostate cancer; Ii-key hybrid cancer vaccine AE37; Ii-key hybrid HER2/neu vaccine Antigen Express AE37; Ii-key hybrid HER2/neu vaccine Generex Biotechnology AE37; Ii-Key/Her-2/neu(776-790) vaccine; Modified HER2/neu peptide AE37 vaccine

Latest Information Update: 27 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antigen Express
  • Developer Antigen Express; Merck AG; NSABP Foundation; NuGenerex Immuno-Oncology
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Triple negative breast cancer
  • No development reported Prostate cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 27 Apr 2022 AE 37 is still in phase II trial in Triple negative Breast cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (Intradermal) (NCT04024800)
  • 09 Dec 2021 Efficacy data from a phase IIb trial in Breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS-2021)
  • 09 Dec 2021 Greenwich LifeSciences plans a phase III trial in Breast cancer, by 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top